Avid Bioservices Secures $1.1 Billion Funding to Boost Biologics Manufacturing

Avid Bioservices (NASDAQ: CDMO), a leading contract development and manufacturing organization (CDMO) specializing in biologics, has announced a significant funding milestone, successfully raising $1.1 billion to enhance its operations and expand its services. With over 30 years of experience in the biotechnology and biopharmaceutical sectors, Avid provides a comprehensive suite of services that spans from CGMP clinical and commercial manufacturing to process development for cell and gene therapy industries. The substantial capital raised will be strategically allocated to bolster Avid’s capabilities in process development and to accelerate production capacity, meeting the growing demand for biologics amid a rapidly evolving healthcare landscape. This funding will also allow the company to invest in cutting-edge technologies and infrastructure to streamline their operations, ultimately positioning Avid to better support its clients from early-stage development through commercialization. With an unwavering commitment to quality and client satisfaction, Avid aims to leverage this investment to enhance its market position while ensuring timely and efficient delivery of critical therapies to patients. As Avid shapes the future of biologic manufacturing, they invite stakeholders and interested parties to stay informed about genuine career opportunities by visiting their official careers page, especially in light of the recent warnings about fraudulent job postings in the industry.